全文获取类型
收费全文 | 357篇 |
免费 | 33篇 |
国内免费 | 1篇 |
专业分类
391篇 |
出版年
2022年 | 2篇 |
2021年 | 8篇 |
2020年 | 4篇 |
2019年 | 3篇 |
2018年 | 7篇 |
2017年 | 4篇 |
2016年 | 8篇 |
2015年 | 17篇 |
2014年 | 26篇 |
2013年 | 18篇 |
2012年 | 22篇 |
2011年 | 25篇 |
2010年 | 9篇 |
2009年 | 9篇 |
2008年 | 19篇 |
2007年 | 19篇 |
2006年 | 15篇 |
2005年 | 12篇 |
2004年 | 19篇 |
2003年 | 12篇 |
2002年 | 11篇 |
2001年 | 6篇 |
2000年 | 3篇 |
1999年 | 6篇 |
1993年 | 2篇 |
1992年 | 5篇 |
1991年 | 8篇 |
1989年 | 3篇 |
1988年 | 2篇 |
1987年 | 4篇 |
1986年 | 5篇 |
1985年 | 8篇 |
1984年 | 4篇 |
1983年 | 8篇 |
1982年 | 2篇 |
1981年 | 3篇 |
1976年 | 2篇 |
1975年 | 3篇 |
1974年 | 4篇 |
1973年 | 2篇 |
1972年 | 3篇 |
1971年 | 7篇 |
1970年 | 2篇 |
1969年 | 3篇 |
1968年 | 5篇 |
1967年 | 4篇 |
1966年 | 4篇 |
1965年 | 3篇 |
1960年 | 1篇 |
1959年 | 1篇 |
排序方式: 共有391条查询结果,搜索用时 0 毫秒
41.
Thomas TP Myaing MT Ye JY Candido K Kotlyar A Beals J Cao P Keszler B Patri AK Norris TB Baker JR 《Biophysical journal》2004,86(6):3959-3965
The utility of a two-photon optical fiber fluorescence probe (TPOFF) for sensing and quantifying tumor fluorescent signals was tested in vivo. Xenograft tumors were developed in athymic mice using MCA207 cells expressing green fluorescent protein (GFP). The TPOFF probe was able to detect ex vivo fluorescence from excised tumors containing as little as 0.3% GFP-expressing cells. TPOFF results were similar to both flow-cytometric analysis of tumor cells after isolation and suspension, and fluorescence determined by microscope images of cryosectioned tumors. TPOFF was then used to measure GFP fluorescence from tumors in live mice. The fiber probe detected fluorescently-labeled Herceptin antibody targeted to HER2-expressing tumors in severe combined immunodeficient mice. Dendrimer nanoparticles targeted by folic acid and having 6-TAMRA as a fluorescent probe were also used to label KB cell tumors in vivo. The fiber probe documented a fourfold increase in tumor fluorescence in animals that received the targeted dendrimer. These results suggest TPOFF can be used as a minimally invasive system for identifying tumor markers and monitoring drug therapy. 相似文献
42.
Anita Rózsás Judit Berta Lívia Rojkó László Z. Horváth Magdolna Keszthelyi István Kenessey Viktória László Walter Berger Michael Grusch Mir Alireza Hoda Szilvia T?r?k Walter Klepetko Ferenc Rényi-Vámos Balázs Heged?s Balázs D?me József Tóvári 《PloS one》2013,8(10)
Recombinant human erythropoietins (rHuEPOs) are used to treat cancer-related anemia. Recent preclinical studies and clinical trials, however, have raised concerns about the potential tumor-promoting effects of these drugs. Because the clinical significance of erythropoietin receptor (EPOR) signaling in human non-small cell lung cancer (NSCLC) also remains controversial, our aim was to study whether EPO treatment modifies tumor growth and if EPOR expression has an impact on the clinical behavior of this malignancy. A total of 43 patients with stage III–IV adenocarcinoma (ADC) and complete clinicopathological data were included. EPOR expression in human ADC samples and cell lines was measured by quantitative real-time polymerase chain reaction. Effects of exogenous rHuEPOα were studied on human lung ADC cell lines in vitro. In vivo growth of human ADC xenografts treated with rHuEPOα with or without chemotherapy was also assessed. In vivo tumor and endothelial cell (EC) proliferation was determined by 5-bromo-2’-deoxy-uridine (BrdU) incorporation and immunofluorescent labeling. Although EPOR mRNA was expressed in all of the three investigated ADC cell lines, rHuEPOα treatment (either alone or in combination with gemcitabine) did not alter ADC cell proliferation in vitro. However, rHuEPOα significantly decreased tumor cell proliferation and growth of human H1975 lung ADC xenografts. At the same time, rHuEPOα treatment of H1975 tumors resulted in accelerated tumor endothelial cell proliferation. Moreover, in patients with advanced stage lung ADC, high intratumoral EPOR mRNA levels were associated with significantly increased overall survival. This study reveals high EPOR level as a potential novel positive prognostic marker in human lung ADC. 相似文献
43.
Marchais-Oberwinkler S Nowicki B Pike VW Halldin C Sandell J Chou YH Gulyas B Brennum LT Farde L Wikström HV 《Bioorganic & medicinal chemistry》2005,13(3):883-893
WAY-100635 [N-(2-(1-(4-(2-methoxyphenyl)piperazinyl)ethyl))-N-(2-pyridinyl)cyclohexanecarboxamide] 1 and its O-desmethyl derivative DWAY 2 are well-known high affinity 5-HT(1A) receptor antagonists, which when labeled with carbon-11 (beta+; t(1/2) = 20.4 min) in the carbonyl group are effective radioligands for imaging brain 5-HT(1A) receptors with positron emission tomography (PET). In a search for new 5-HT(1A) antagonists with different pharmacokinetic and metabolic properties, the pyridinyl N-oxide moiety was incorporated into analogs of 1 and 2. NOWAY 3, in which the pyridinyl ring of 1 was oxidized to the pyridinyl N-oxide, was prepared via nucleophilic substitution of 2-[4-(2-methoxyphenyl)piperazin-1-yl]ethylamine on 2-chloropyridine-N-oxide followed by acylation with cyclohexanecarbonyl chloride. 6Cl-NOWAY 4, a more lipophilic (pyridinyl-6)-chloro derivative of 3, was prepared by treating 1-(2-methoxyphenyl)-4-(2-(2-(6-bromo)aminopyridinyl-N-oxide)ethyl)piperazine with cyclohexanecarbonyl chloride for acylation and concomitant chloro for bromo substitution. NEWWAY 5, in which the 2-hydroxy-phenyl group of 2 is replaced with a 2-pyridinyl N-oxide group with the intention of mimicking the topology of 2, was prepared in five steps from 2-(chloroacetylamino)pyridine. N-Oxides 3-5 were found to be high affinity antagonists at 5-HT(1A) receptors, with 3 having the highest affinity and a Ki value (0.22 nM) comparable to that of 1 (0.17 nM). By calculation the lipophilicity of 3 (LogP = 1.87) is lower than that of 1 by 1.25 LogP units while TLC and reverse phase HPLC indicate that 3 has slightly lower lipophilicity than 1. On the basis of these encouraging findings, the N-oxide 3 was selected for labeling with carbon-11 in its carbonyl group and for evaluation as a radioligand with PET. After intravenous injection of [carbonyl-11C]3 into cynomolgus monkey there was very low uptake of radioactivity into brain and no PET image of brain 5-HT(1A) receptors was obtained. Either 3 inadequately penetrates the blood-brain barrier or it is excluded from brain by an active efflux mechanism. Rapid deacylation of 3 was not apparent in vivo; in cynomolgus monkey plasma radioactive metabolites of [carbonyl-11C]3 appeared less rapidly than from the radioligands [carbonyl-11C]1 and [carbonyl-11C]2, which are known to be primarily metabolized by deacylation. Ligand 3 may have value as a new pharmacological tool, but not as a radioligand for brain imaging. 相似文献
44.
Xinshou Ouyang Sheng-Na Han Ji-Yuan Zhang Evangelos Dioletis Balazs Tamas Nemeth Pal Pacher Dechun Feng Ramon Bataller Joaquin Cabezas Peter Stärkel Joan Caballeria Rebecca LePine Pongratz Shi-Ying Cai Bernd Schnabl Rafaz Hoque Yonglin Chen Wei-hong Yang Irma Garcia-Martinez Wajahat Zafar Mehal 《Cell metabolism》2018,27(2):339-350.e3
45.
S-genotyping of old apple cultivars from the Carpathian basin: methodological, breeding and evolutionary aspects 总被引:1,自引:0,他引:1
Julia Hal��sz Attila Heged?s Zsuzsanna Gy?rgy ��va P��llinger Magdolna T��th 《Tree Genetics & Genomes》2011,7(6):1135-1145
Apple exhibits self-incompatibility controlled by the multiallelic S-locus. Twenty-three old apple cultivars were S-genotyped using three different approaches (allele-specific polymerase chain reaction (PCR) + cleaved amplified polymorphic
sequences (CAPS), consensus PCR + sequencing and consensus PCR + CAPS) to compare the robustness and reliability of these
techniques and characterise genotypes from the Carpathian basin that might be useful in resistance breeding. Best results
were obtained using the ASPF3 and ASPR3S consensus primer pair that detected 96% of all alleles carried by the 23 cultivars
tested. Flow cytometry analysis was also needed to control the completeness of the genotypes as was seen in case of a tetraploid
cultivar with only three assigned S-alleles. The genetic disparity between the old Carpathian basin and modern apple cultivars was indicated by differences in
allele frequency data (S
9, S
24 and S
26) as well as single nucleotide polymorphisms in S
1, S
2, S
7
S
24 and S
26 and indels in S
20 and S
26 alleles. An alignment of partial genomic sequences indicated trans-specific and trans-generic evolution of S-ribonuclease alleles in the Maloideae subfamily (S
26 and S
28) and a possibly recent introgression event (S
1) between Malus × domestica and Malus sylvestris. These data suggest that the genome of old cultivars from the Carpathian basin was enriched by several Malus taxa and are free from the consequences of modern breeding. These cultivars may contribute to the widening of the genetic
basis of cultivated apple and prevent genetic erosion in future commercial cultivars. 相似文献
46.
47.
48.
49.
50.
Zhenhai Chen Pei Xu Gregory W. Salyards Stephen B. Harvey Balazs Rada Zhen F. Fu Biao He 《PloS one》2012,7(11)
Parainfluenza virus 5 (PIV5), formerly known as simian virus 5 (SV5), is a paramyxovirus often referred to as canine parainfluenza virus (CPI) in the veterinary field. PIV5 is thought to be a contributing factor to kennel cough. Kennel cough vaccines containing live PIV5 have been used in dogs for many decades. PIV5 is not known to cause any diseases in humans or other animals. PIV5 has been used as a vector for vaccine development for humans and animals. One critical question concerning the use of PIV5 as a vector is whether prior exposure to PIV5 would prevent the use of PIV5-based vaccines. In this work, we have examined immunogenicity of a recombinant PIV5 expressing hemagglutinin (HA) of influenza A virus subtype 3 (rPIV5-H3) in dogs that were immunized against PIV5. We found that vaccination of the dogs containing neutralizing antibodies against PIV5 with rPIV5-H3 generated immunity against influenza A virus, indicting that PIV5-based vaccine is immunogenic in dogs with prior exposure. Furthermore, we have examined exposure of PIV5 in human populations. We have detected neutralizing antibody (nAb) against PIV5 in 13 out of 45 human serum samples (about 29 percent). The nAb titers in humans were lower than that in vaccinated dogs, suggesting that nAb in humans is unlikely to prevent PIV5 from being an efficacious vector in humans. 相似文献